| Ticker: EMED | Wilhelminakanaal Noord 6 | |
| Exchange: NASDAQ-National Market | Oosterhout, Foreign NL 4902 VR | |
| Industry: Wholesale | 1162424424 |
| Type of Shares: | Common Shares | Filing Date: | 12/22/95 | |
| U.S. Shares: | 1,000,000 | Offer Date: | 3/19/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | $6.50 | |
| Primary Shares: | 1,000,000 | Offer Price: | $6.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.65 | |
| Offering Amount: | $6,500,000 | Selling: | $0.32 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 3,000,000 |
| Manager | Tier | Phone |
| National Securities Corp. | Lead Manager | (206) 622-7200 |
| First London Securities Corporation | Co-manager | (206) 220-0690 |
| La Jolla Securities, Inc. | Co-manager | (619) 456-8200 |
| Auditor: KPMG Accountants N.V. | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $32.98 | Assets: | $8.85 | ||
| Net Income: | $0.84 | Liabilities: | $7.73 | ||
| EPS: | $0.42 | Equity: | $1.12 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the parallel import and wholesale distribution of EuroSpecialties, the wholesale distribution of DutchSpecialties and over-the-counter pharmaceuticals within The Netherlands, and the export of generic pharmaceuticals. The company is engaged, through its wholly-owned subsidiaries, Galenica and Confedera, in (i) the parallel import of EuroSpecialties, which are prescription ("ethical") branded pharmaceuticals registered and marketed throughout Europe under international patent and a European brand; (ii) the wholesale distribution of EuroSpecialties and generic pharmaceuticals to pharmacies and other wholesalers in The Netherlands; (iii) the wholesale distribution of DutchSpecialties, which are ethical branded pharmaceuticals under international patent, registered and marketed as a brand specifically within The Netherlands; (iv) the wholesale distribution of over-the-counter ("non-ethical") pharmaceuticals to pharmacies and other wholesalers in The Netherlands; and (v) the export of generic pharmaceuticals to developing nations of the world. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used to finance the company's growth strategy, finance the acquisition and process of pharmaceutical registrations for the parallel import of EuroSpecialties, finance a general expansion of inventory, finance a general increase in the export of generics, repay certain indebtedness and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.